Mayo Clinic Laboratories is aware of the Microsoft outage that is impacting domestic and international shipments. We are actively monitoring the situation and making carrier adjustments as needed
Presented by Mayo Clinic Laboratories, the Classical Hematology Conference, happening Oct. 15–17, is an essential event for professionals in hematology, including medical practitioners, researchers, and laboratory specialists.
William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, authored a Becker’s Healthcare article on how hospital laboratories can navigate times of change and uncertainty with the steadfast support of a business partner like Mayo Clinic Laboratories.
Discover how to harness the power of your outreach program to position your organization for success at the 35th Leveraging the Laboratory: Seize Tomorrow conference, presented by Mayo Clinic Laboratories. This in-person event promises innovative insights into all aspects of health system laboratory outreach programs.
Join us for the Classical Hematology Conference: Nonmalignant Hematology and Bleeding and Thrombotic Disorders, presented by Mayo Clinic Laboratories. This hybrid conference held Oct. 15–17, 2024, in Scottsdale, Arizona, will provide reviews and updates about the laboratory and clinical aspects of nonmalignant hematology and bleeding and thrombotic disorders.
In a landmark discovery published in Clinical Chemistry, authenticated locks of hair from the composer Ludwig van Beethoven have revealed high lead concentrations after being analyzed at Mayo Clinic. Paul Jannetto, Ph.D., director of the Metals Laboratory at Mayo Clinic, along with his laboratory staff, completed testing on two independent and authenticated locks of Beethoven’s hair which confirmed the presence of high lead concentrations and could explain the cause for many of Beethoven’s ailments.
As a successful outcome of the collaboration announced in 2023, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available through Mayo Clinic Laboratories.
Mary Jo Williamson, chief administrative officer of Mayo Clinic Laboratories, joins the “Fierce Healthcare” podcast to discuss how organizations can cultivate resiliency and agility amidst a changing healthcare landscape.
William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, is a contributing author on Nasdaq.com. In his latest article, he discusses sustainability in laboratories and the interconnectivity of environmental health and public health.
Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative of amyloid beta accumulation in the brain. This test is set to transform the approach to Alzheimer's disease management, offering a convenient and less invasive alternative to traditional diagnostic methods.
Mayo Clinic Laboratories introduces an advancement in the management of Crohn's disease with the release of a new laboratory test that measures Risankizumab levels in patients. This test will advance the therapeutic monitoring of Crohn's disease, enabling personalized treatment approaches.
BioPharma Diagnostics executives will attend the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit, set to take place in Boston, Massachusetts, from April 23 –25. They will be available to meet with attendees to discuss how our capabilities and data can accelerate biopharmaceutical and clinical research initiatives.
In recent articles, Mayo Clinic Laboratories emphasizes the transformative potential of recognizing and leveraging the capabilities of a hospital laboratory. With more touchpoints than any other outpatient service line, the laboratory is full of opportunity to enhance local healthcare delivery and bolster a hospital’s financial stability.